NASDAQ$APGE
Apogee Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
APGE Q1 2024 — $1.24B revenue
There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this Quarterly Rep. Apogee Therapeutics Inc reported Q1 2024 results. Net income of $32.1M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $1.24B.
- Net income: $32.1M.
- Filed on Form 10-Q (accession 0001558370-24-007861).
Headline financials
Revenue & EPS history
Apogee · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2024
+5.6%
Avg return
Earnings day
+9.2%
Avg return
5 days after
+10.9%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+59.8%
Q4 2023
Best reaction
-12.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +4.4% | +20.3% | |
| Q3 2025 | +3.8% | +19.7% | +39.0% | |
| Q2 2025 | -2.2% | +5.4% | +5.9% | |
| Q1 2025 | -0.0% | -1.1% | +9.4% | |
| Q4 2024 | -0.2% | +14.9% | +20.3% | |
| Q3 2024 | -12.7% | -21.8% | -26.7% | |
| Q2 2024 | +9.7% | +11.7% | +25.0% | |
| Q1 2023 | +1.5% | -5.5% | -16.7% | |
| Q1 2024 | +1.5% | -5.5% | -16.7% | |
| Q4 2023 | +59.8% | +61.8% | +41.4% | |
| Q3 2023 | +12.8% | +20.6% | +45.9% | |
| Q3 2022 | +12.8% | +20.6% | +45.9% | |
| Q4 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2022 | -1.1% | +4.0% | -9.6% | |
| Q2 2023 | -1.1% | +4.0% | -9.6% | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro